Over the last few years, Curetis has created a down-to-earth and continuous success story. It all began with the Unyvero product idea and progressed through the development and approval procedure towards tapping into the international medical technology markets. From the outset, the company has impressed with its high awareness of quality combined with a strong pioneering spirit and the simple claim: "We care for diagnostics". This success was due, in no small part, to the outstanding engineering capabilities and molecular and microbiological expertise of both our investors and our customers and partners.
Curetis' growth potential lies, on the one hand, in developing and expanding the world's national markets and, on the other hand, in extending the Unyvero system with a continuous stream of new cartridges for additional infectious diseases.
Subscribe to Curetis Newsletter
Curetis Announces Financial Results for the First Six Months of 2018
Curetis Announces Change in Curetis USA Inc. Management
BOA 2018, British Orthopaedic Association - Birmingham, United Kingdom - September 25 to 28, 2018
ID Week - Infectious Disease 2018 - San Fransisco, USA - October 3 to 7, 2018